Pune, May 25, 2020 (GLOBE NEWSWIRE) -- The global cardiac biomarkers market size is expected to reach USD 26.33 billion by 2027, exhibiting a CAGR of 11.2% during the forecast period. The growing incidence of critical cardiac conditions, including myocardial infarction, heart attack, and acute coronary syndrome (ACS) will subsequently inflate demand for cardiac biomarkers in the forthcoming years, mentioned in a report, titled “Cardiac Biomarkers Market Size, Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027” the market size stood at USD 13.15 billion in 2019. The increasing prevalence of cardiovascular diseases will spur opportunities for the market during the forecast period.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-biomarkers-market-101233
Market Driver:
Cardiovascular Interventions to Promote Biomarkers Adoption
The increasing R&D investments by key players for the introduction of robust and novel cardiac biomarkers to benefit patients in diagnosis, prognosis and predictive analysis of cardiovascular disorders will enable speedy expansion of the market. The innovation in clinical cardiology and cardiovascular interventions can be an essential factor in fostering the growth of the market. Moreover, the increasing product launches by key players will augur well for the market in the forthcoming years.
For instance, In July 2018, Siemens announced that it has received the U.S. Food and Drug Administration (FDA) approval for high-sensitivity troponin I assays (TnIH). The test will be beneficial in the early diagnosis of myocardial infarctions without the need for serial tropic testing. Similarly, in September 2019, Abbott unveiled ARCHITECT STAT High Sensitivity Troponin-I blood test after receiving the approval from the U.S. Food and Drug Administration (FDA) approval. The test will help in detecting heart attacks in real-time, and more accurately than contemporary troponin tests.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
To get the short-term and long-term impact of COVID-19 on this Market.
Please visit: https://www.fortunebusinessinsights.com/industry-reports/cardiac-biomarkers-market-101233
Market Restraint:
Shortage of POC Testing Kits to Restrict Revenue Proliferation
The unavailability of POC testing kits and delayed test results of the laboratory-based tests will consequently restrict the growth of the market. The longer time period required to obtain results from lab-based biomarker tests will dwindle the acceptance of biomarkers in the forthcoming years. For instance, creatine kinase-MB (CK-MB), a form of enzyme found in heart muscle cells can only be detected in a patient with a heart attack in about 3-6 hours after the onset of chest pain. Thus, the great deal of time required for evaluation or diagnosis of heart disease will restrict the market growth. In addition, the lack of awareness regarding cardiac biomarkers tests among patient population, and limited reimbursement for tests in the developing countries will obstruct the market.
Regional Analysis:
Increasing Prevalence of Cardiovascular Diseases to Propel Market in North America
The market in North America stood at USD 5.23 billion in 2019. North America is expected to the largest market share during the forecast period owing to the rising prevalence of cardiovascular diseases. For instance, as per the American College of Cardiology Foundation around about 1.05 million patients were suffering from coronary disorders in the United States in 2019. Europe is predicted to witness a high growth rate between 2020 to 2027 due to rising cases of acute coronary syndrome and myocardial infarction. Asia Pacific is likely to grow rapidly during the forecast period owing to the large patient population in the region. Moreover, the introduction of technologically advanced cardiac biomarkers will boost cardiac biomarkers market growth in Asia Pacific.
Quick Buy - Cardiac Biomarkers Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101233
Key Development:
May 2016: Philips, a Dutch multinational conglomerate corporation headquartered in Amsterdam launched Minicare I-20 system for cardiac troponin testing. The handheld blood test for rapid diagnosis of heart attack.
List of the Prominent Companies in the Cardiac Biomarkers Market are:
- F. Hoffmann-La Roche AG
- Abbott
- Siemens AG
- Creative Diagnostics
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- Others
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/cardiac-biomarkers-market-101233
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Prevalence of Cardiovascular Disorders, By Key Regions/ Key Countries, 2019
- Overview of Impact of COVID-19 on the In-vitro Diagnostics Market
- New Product Launches, By Key Market Players
- Key Industry Developments such as Mergers and Acquisitions
- Key Steps Taken by Companies, Government, etc. to Navigate the Impact of Covid-19
- Overview: Impact of Covid-19 on Cardiac Tests
- Global Cardiac Biomarkers Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Indication
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Others
- Market Analysis, Insights and Forecast – By Biomarkers
- Troponin
- Creatine kinase-MB (CK-MB)
- B-type natriuretic peptide (BNP)
- Myoglobin
- Others
- Market Analysis, Insights and Forecast – By End User
- Hospitals
- Speciality Clinics
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia pacific
- Latin America
- Middle East & Africa
Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/cardiac-biomarkers-market-101233
Have a Look at Related Reports:
Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026
Cardiac Pacemaker Market Size, Share and Industry Analysis By Product (Single Chamber Pacemakers, Dual Chamber Pacemakers, Cardiac Resynchronization Therapy-Pacemakers (CRT-P)), By End User (Hospitals & Clinics, Ambulatory Surgery Centers and Others), and Regional Forecast 2019-2026
Cardiac Rhythm Management (CRM) Devices Market Size, Share and Industry Analysis Product By (Cardiac Pacemakers, Defibrillators, Cardiac Resynchronization Therapy Devices) By End User (Hospitals & Clinics, Ambulatory Surgery Centers), and Regional Forecast, 2019 - 2026
Coronary Guidewires Market Size, Share & Industry Analysis, By Material (Nitinol, Stainless Steel, and Others) By Coating (Coated and Non-Coated) By End User (Hospitals, Cardiac Catheterization Laboratories, and Others) and Regional Forecast, 2019-2026
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/cardiac-biomarkers-market-9940